162 related articles for article (PubMed ID: 17985985)
1. A phase II study of gefitinib in patients with advanced thyroid cancer.
Pennell NA; Daniels GH; Haddad RI; Ross DS; Evans T; Wirth LJ; Fidias PH; Temel JS; Gurubhagavatula S; Heist RS; Clark JR; Lynch TJ
Thyroid; 2008 Mar; 18(3):317-23. PubMed ID: 17985985
[TBL] [Abstract][Full Text] [Related]
2. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
3. Motesanib diphosphate in progressive differentiated thyroid cancer.
Sherman SI; Wirth LJ; Droz JP; Hofmann M; Bastholt L; Martins RG; Licitra L; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Schlumberger MJ;
N Engl J Med; 2008 Jul; 359(1):31-42. PubMed ID: 18596272
[TBL] [Abstract][Full Text] [Related]
4. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
Lim SM; Chang H; Yoon MJ; Hong YK; Kim H; Chung WY; Park CS; Nam KH; Kang SW; Kim MK; Kim SB; Lee SH; Kim HG; Na II; Kim YS; Choi MY; Kim JG; Park KU; Yun HJ; Kim JH; Cho BC
Ann Oncol; 2013 Dec; 24(12):3089-94. PubMed ID: 24050953
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
[TBL] [Abstract][Full Text] [Related]
7. Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Borson-Chazot F; Dantony E; Illouz F; Lopez J; Niccoli P; Wassermann J; Do Cao C; Leboulleux S; Klein M; Tabarin A; Eberle MC; Benisvy D; de la Fouchardière C; Bournaud C; Lasolle H; Delahaye A; Rabilloud M; Lapras V; Decaussin-Petrucci M; Schlumberger M
Thyroid; 2018 Sep; 28(9):1174-1179. PubMed ID: 30105951
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma.
Masaki C; Sugino K; Saito N; Saito Y; Tanaka T; Ogimi Y; Maeda T; Osaku T; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Takami H; Ito K
Endocr J; 2017 Aug; 64(8):819-826. PubMed ID: 28659544
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Locati LD; Licitra L; Agate L; Ou SH; Boucher A; Jarzab B; Qin S; Kane MA; Wirth LJ; Chen C; Kim S; Ingrosso A; Pithavala YK; Bycott P; Cohen EE
Cancer; 2014 Sep; 120(17):2694-703. PubMed ID: 24844950
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.
Sherman EJ; Dunn LA; Schöder H; Ho AL; Baxi SS; Ghossein RA; Haque SS; Sima C; Tuttle RM; Pfister DG
Cancer; 2019 Sep; 125(17):2984-2990. PubMed ID: 31174237
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Molina-Vega M; García-Alemán J; Sebastián-Ochoa A; Mancha-Doblas I; Trigo-Pérez JM; Tinahones-Madueño F
Endocrine; 2018 Feb; 59(2):395-401. PubMed ID: 29275532
[TBL] [Abstract][Full Text] [Related]
12. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
Schneider TC; de Wit D; Links TP; van Erp NP; van der Hoeven JJ; Gelderblom H; Roozen IC; Bos M; Corver WE; van Wezel T; Smit JW; Morreau H; Guchelaar HJ; Kapiteijn E
J Clin Endocrinol Metab; 2017 Feb; 102(2):698-707. PubMed ID: 27870581
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib in metastatic thyroid cancer.
Capdevila J; Iglesias L; Halperin I; Segura A; Martínez-Trufero J; Vaz MÁ; Corral J; Obiols G; Grande E; Grau JJ; Tabernero J
Endocr Relat Cancer; 2012 Apr; 19(2):209-16. PubMed ID: 22285864
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.
Matuszczyk A; Petersenn S; Bockisch A; Gorges R; Sheu SY; Veit P; Mann K
Horm Metab Res; 2008 Mar; 40(3):210-3. PubMed ID: 18348081
[TBL] [Abstract][Full Text] [Related]
16. The use of thyrogen in the treatment of differentiated thyroid carcinoma: an intraindividual comparison of clinical effects and implications of daily life.
Dueren C; Dietlein M; Luster M; Plenzig F; Steinke R; Grimm J; Groth P; Eichhorn W; Reiners C
Exp Clin Endocrinol Diabetes; 2010 Aug; 118(8):513-9. PubMed ID: 19856258
[TBL] [Abstract][Full Text] [Related]
17. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma.
Simon D; Koehrle J; Reiners C; Boerner AR; Schmutzler C; Mainz K; Goretzki PE; Roeher HD
World J Surg; 1998 Jun; 22(6):569-74. PubMed ID: 9597930
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
Asahina H; Oizumi S; Inoue A; Kinoshita I; Ishida T; Fujita Y; Sukoh N; Harada M; Maemondo M; Saijo Y; Dosaka-Akita H; Isobe H; Nukiwa T; Nishimura M;
Oncology; 2010; 79(5-6):423-9. PubMed ID: 21474967
[TBL] [Abstract][Full Text] [Related]
20. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Woyach JA; Kloos RT; Ringel MD; Arbogast D; Collamore M; Zwiebel JA; Grever M; Villalona-Calero M; Shah MH
J Clin Endocrinol Metab; 2009 Jan; 94(1):164-70. PubMed ID: 18854394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
